FOXO Technologies Inc.
0.0009-0.00 (-10%)
Oct 29, 3:48:37 PM EDT · NYSE American · FOXO · USD
Key Stats
Market Cap
69.00KP/E (TTM)
-Basic EPS (TTM)
-10.29Dividend Yield
0%Recent Filings
8-K
8-K
CFO appointment and preferred stock amendment
FOXO Technologies appointed Sylwia Nowak Hauman as Chief Financial Officer effective September 23, 2025, bringing her 25 years of finance expertise from biotech firms like Aditxt and Lonza to bolster financial oversight. The company also amended its Certificate of Incorporation on September 22, 2025, boosting authorized Series A Preferred Stock shares to 50,000 while tweaking voting rights, conversion terms, and adding cash dividends for Series E holders. This dual move strengthens governance amid capital structure shifts. Leadership refresh hits now.
8-K
Share authorization surges approved
FOXO Technologies' majority stockholder, holding 56.71% of voting rights and controlled by the CEO, approved via written consent on September 10, 2025, an amendment to boost authorized Class A common shares from 500 million to 2.5 billion, effective at board discretion before March 31, 2026. This move, set to activate 20 days after mailing the definitive Schedule 14C to shareholders, equips the company for potential equity raises or issuances. Yet dilution looms for minority holders.
8-K
FOXO acquires Vector Biosource
FOXO Technologies signed a stock purchase agreement on September 11, 2025, to acquire Vector Biosource, a provider of information, data, and biospecimens for biotech, clinical research, and pharma sectors. The deal includes $500,000 cash, Series E Preferred Stock worth $1.5 million, warrants for $2 million in common stock, and up to $2 million more in preferred stock tied to revenue milestones, with closing pending due diligence. Vector posted Q2 2025 net revenues of $225,000, signaling a modest entry into healthcare services. FOXO commits $1.2 million to fuel Vector's organic expansion and potential add-ons, yet integration hinges on volatile biotech demands.
8-K
FOXO acquires Vector BioSource
FOXO Technologies entered a stock purchase agreement on September 9, 2025, to acquire Vector BioSource for $500,000 cash, 60,000 shares of Series E Preferred Stock, warrants for up to $2,000,000 in common stock, and up to 80,000 additional preferred shares contingent on hitting $4,000,000 in qualifying revenue by the second anniversary. Closing awaits due diligence, warrant finalization, employment pacts, and $1.2 million funding for a 12-month budget. Sellers can repurchase shares under narrow terms. This bolsters FOXO's biotech footprint, yet ties rewards to revenue milestones.
IPO
Employees
Sector
Industry
BEAT
Heartbeam, Inc.
1.60+0.01
DRIO
DarioHealth Corp.
14.05-1.28
ESSI
Eco Science Solutions, Inc.
0.02-0.00
FORA
Forian Inc.
2.33-0.02
GEHC
GE HealthCare Technologies Inc.
77.38-2.02
HYDTF
Hydreight Technologies Inc
3.28-0.09
LVCE
LIVECARE INC
0.03+0.00
SOPH
SOPHiA GENETICS SA
4.54+0.45
TDOC
Teladoc Health, Inc.
8.23-0.13
TEM
Tempus AI, Inc.
88.84+2.25